Search Result
Results for "
PTP1B inhibitor
" in MedChemExpress (MCE) Product Catalog:
| Cat. No. |
Product Name |
Target |
Research Areas |
Chemical Structure |
-
- HY-12219A
-
|
Trodusquemine lactate; Aminosterol-1436 lactate
|
Phosphatase
|
Endocrinology
|
|
MSI-1436 lactate is a selective, non-competitive inhibitor of the enzyme protein-tyrosine phosphatase 1B (PTP1B), with an IC50 of 1 μM, 200-fold preference over TCPTP (IC50 of 224 μM).
|
-
-
- HY-10704
-
-
-
- HY-N1549
-
Prunin
4 Publications Verification
Naringenin 7-0-glucoside
|
Enterovirus
Phosphatase
|
Infection
Metabolic Disease
|
|
Prunin is a potent inhibitor of human enterovirus A71 (HEVA71). Prunin shows strong inhibitory activity against protein tyrosine phosphatase 1B (PTP1B), with an IC50 of 5.5 μM .
|
-
-
- HY-121515
-
|
|
Phosphatase
|
Metabolic Disease
|
|
DPM-1001 is a potent, specific, orally active and non-competitive inhibitor of protein-tyrosine phosphatase (PTP1B) with an IC50 of 100 nM. DPM-1001 is an analog of the specific PTP1B inhibitor MSI-1436. DPM-1001 has anti-diabetic property .
|
-
-
- HY-112368
-
-
-
- HY-100462
-
-
-
- HY-N0374
-
|
|
Glycosidase
|
Metabolic Disease
|
|
Licochalcone C could inhibit α-glucosidase, with IC50s of <100 nM and 92.43 μM for α-glucosidase and protein tyrosine phosphatase 1B (PTP1B), respectively.
|
-
-
- HY-12219
-
|
Trodusquemine; Aminosterol-1436
|
Phosphatase
|
Endocrinology
|
|
MSI-1436 is a selective, non-competitive inhibitor of the enzyme protein-tyrosine phosphatase 1B (PTP1B), with an IC50 of appr 1 μM, 200-fold preference over TCPTP (IC50, 224 μM).
|
-
-
- HY-123966
-
|
|
Phosphatase
|
Neurological Disease
|
|
MY33-3 is a potent and selective inhibitor of receptor protein tyrosine phosphatase (RPTP)β/ζ, with an IC50 of ~0.1 μM. MY33-3 also inhibits PTP-1B (IC50 ~0.7 μM). MY33-3 can reduce ethanol consumption and alleviate Sevoflurane-induced neuroinflammation and cognitive dysfunction .
|
-
-
- HY-101964
-
SPI-112
1 Publications Verification
|
SHP2
Phosphatase
|
Cancer
|
|
SPI-112 is a potent, selective and competitive SHP2 (PTPN11) inhibitor with IC50s of 1 μM, 18.3 μM and 14.5 μM for SHP2, protein tyrosine phosphatase (PTP) and PTP1B, respectively .
|
-
-
- HY-15756
-
|
|
Phosphatase
|
Metabolic Disease
|
|
PTP1B-IN-4 is a non-competitive allosteric inhibitor of the protein tyrosine phosphatase PTP1B, with an IC50 of 8 μM. PTP1B-IN-4 is potentail for the research of obesity and diabetes .
|
-
-
- HY-12312
-
-
-
- HY-153446
-
|
PTPN2/1-IN-1
|
Phosphatase
|
Cancer
|
|
Tegeprotafib (PTPN2/1-IN-1) (Compound 124) is an orally active PTPN1 and PTPN2 inhibitor with IC50s of 4.4 nM and 1-10 nM against PTPN2 and PTP1B, respectively .
|
-
-
- HY-15133
-
|
|
Phosphatase
|
Metabolic Disease
Cancer
|
|
PTP1B-IN-3 is a potent and orally active PTP1B inhibitor with IC50s of 120 nM for both PTP1B and TCPTP. PTP1B-IN-3 has antidiabetic and anticancer effects .
|
-
-
- HY-164864
-
|
|
PROTACs
STAT
|
Cancer
|
|
DU-14 (PTP1B/TC-PTP PROTAC) is a potent and selective PTP1B and TC-PTP dual PROTAC degrader. DU-14 (PTP1B/TC-PTP PROTAC) has the IC50 for PTP1B and TC-PTP phosphatase activity of 24.2 nM and 30.1 nM, respectively. DU-14 (PTP1B/TC-PTP PROTAC) enhances IFN-γ signaling, promotes T cell activation, and has anti-tumor activity. (Pink: PTP1B/TC-PTP inhibitor (HY-171027); Black: Linker (HY-W340290); Blue: E3 ligand (HY-112078)) .
|
-
-
- HY-N9326
-
|
|
Phosphatase
|
Metabolic Disease
|
|
Uralenol is a natural PTP1B inhibitor (IC50=21. 5 μM) from Broussonetia papyrifera. PTP1B have been shown to play a major role in the dephosphorylation of the insulin receptor in many cellular and biochemical studies .
|
-
-
- HY-19383
-
|
PTP 112
|
Phosphatase
IKK
PPAR
|
Metabolic Disease
|
|
Ertiprotafib is an inhibitor of PTP1B, IkB kinase β (IKK-β), and a dual PPARα and PPARβ agonist, with an IC50 of 1.6 μM for PTP1B, 400 nM for IKK-β, an EC50 of ~1 μM for PPARα/PPARβ.
|
-
-
- HY-N1789
-
|
|
Phosphatase
Others
|
Others
|
|
Kaempferol-7,4'-dimethyl ether is a PTP1B inhibitor, and also can inhibit the production of NO. Kaempferol-7,4'-dimethyl ether shows the inhibition rate of 46.1% at 100 μM. Kaempferol-7,4'-dimethyl ether inhibits PTP1B activity with IC50 value of 16.92 μM .
|
-
-
- HY-N4185
-
|
|
Phosphatase
|
Neurological Disease
|
|
Licoflavone A is a flavonoid isolated from the roots of Glycyrrhiza uralensis, inhibits protein tyrosine phosphatase-1B (PTP1B), with an IC50 of 54.5 μM .
|
-
-
- HY-161321
-
|
|
Phosphatase
Insulin Receptor
Akt
|
Metabolic Disease
|
|
PTP1B-IN-24 (Compound 9) is a reversible PTP1B inhibitor with an IC50 value of 1.4 μM, and PTP1B-IN-24 can enhance the thermal stability of PTP1B. PTP1B-IN-24 can restore PA- (HY-N0830) induced insulin resistance by increasing the phosphorylation levels of IRS1 and AKT .
|
-
-
- HY-121515A
-
|
|
Phosphatase
|
Metabolic Disease
|
|
DPM-1001 trihydrochloride is a potent, specific, orally active and non-competitive inhibitor of protein-tyrosine phosphatase (PTP1B) with an IC50 of 100 nM. DPM-1001 trihydrochloride is an analog of the specific PTP1B inhibitor MSI-1436. DPM-1001 trihydrochloride has anti-diabetic property .
|
-
-
- HY-115605
-
|
|
EGFR
p38 MAPK
ERK
Phosphatase
|
Cancer
|
|
CN009543V is an epidermal growth factor receptor (EGFR) agonist. CN009543V enhances tyrosine phosphorylation of EGFR at Tyr1068 and Tyr1173, thereby activating the MAPK/ERK cascade. CN009543V inhibits the activity of PTP-1B in MDA MB468 cells. CN009543V can be used in cancer research .
|
-
-
- HY-141800
-
|
|
Phosphatase
|
Others
|
|
MurA-IN-1 (compound 1a) is a PTPRR inhibitor, with IC50 values of 0.23 μM, 0.8 μM, 0.75 μM and 0.09 μM for PTP1B, PTPN5, PTPN7 and PTPRR, respectively . (A family of human MAPK-specific protein tyrosine phosphatases)
|
-
-
- HY-19779
-
|
|
Phosphatase
|
Metabolic Disease
|
|
JTT 551 is selective a protein tyrosine phosphatase 1B (PTP1B) inhibitor, with Kis of 0.22 μM and 9.3 μM for PTP1B and TCPTP (T-cell protein tyrosine phosphatase), respectively; JTT 551 can be used in the research of type 2 diabetes mellitus.
|
-
-
- HY-N6650
-
|
|
Phosphatase
|
Metabolic Disease
|
|
Isotanshinone IIA, an abietane-type diterpene metabolite, could non-competitively inhibit Protein Tyrosine Phosphatase 1B (PTP1B) activity with an IC50 0f 11.4 μM.
|
-
-
- HY-N10002
-
|
|
Phosphatase
Glycosidase
|
Metabolic Disease
|
|
Caffeoyltryptophan is a competitive PTP1B inhibitor, with an IC50 of 16.99 μM. Caffeoyltryptophan can also inhibit α-glucosidase, linoleic acid peroxidation and haemolysis. Caffeoyltryptophan can be used for the research of type 2 diabetes .
|
-
-
- HY-120901
-
|
|
SHP2
SHP1
|
Cancer
|
|
II-B08 is a reversible and noncompetitive SHP2 inhibitor (IC50: 5.5 μM, 15.7, 14.3 μM for SHP2, SHP1, PTP1B). II-B08 can be used for cancer research .
|
-
-
- HY-111469
-
|
|
Phosphatase
|
Metabolic Disease
|
|
CPT-157633, a difluoro-phosphonomethyl phenylalanine derivative, and is a PTP1B inhibitor. CPT-157633 prevents binge drinking-induced glucose intolerance .
|
-
-
- HY-N4143
-
|
|
Phosphatase
|
Metabolic Disease
|
|
Cyanidin 3-arabinoside is a selective and reversible protein tyrosine phosphatase 1B (PTP1B) inhibitor, with an IC50 of 8.91 μM. Cyanidin 3-arabinoside is potential for the research of type 2 diabetes .
|
-
-
- HY-N1230
-
|
Allolicoisoflavone B
|
Phosphatase
|
Inflammation/Immunology
|
|
Sophoraisoflavone A (Allolicoisoflavone B) is a nature product that could be isolated from Glycyrrhiza inflate. Sophoraisoflavone A is a potent protein tyrosine phosphatase 1B (PTP1B) inhibitor with an IC50 value of 0.80 μM. Sophoraisoflavone A can be used in research of inflammation .
|
-
-
- HY-N12177
-
|
|
Phosphatase
SHP1
|
Metabolic Disease
|
|
Cryptosporioptide A (Compound 3) is a pigment protein tyrosine phosphatase inhibitor derived from the insect-parasitic fungus Cordyceps gracilioides. Cryptosporioptide A inhibits PTP1B, SHP2, CDC25B, LAR and SHP1 enzymes with IC50 of 7.3, 5.7, 7.6, >50, 4.9 μg/mL, respectively .
|
-
-
- HY-N3734
-
|
|
Beta-secretase
Phosphatase
|
Neurological Disease
|
|
Deoxyneocryptotanshinone, a natural tanshinone, is a high affinity BACE1 (Beta-secretase) inhibitor with an IC50 value of 11.53 μM. Deoxyneocryptotanshinone shows a promising dose-dependent inhibition of protein tyrosine phosphatase 1B (PTP1B) with an IC50 value of 133.5 μM. Deoxyneocryptotanshinone can be used for Alzheimer's disease research .
|
-
-
- HY-10704R
-
|
PTP1B inhibitor (Standard)
|
Reference Standards
Phosphatase
NF-κB
|
Neurological Disease
Inflammation/Immunology
|
|
PTP1B-IN-1 (Standard) (PTP1B inhibitor (Standard)) is the analytical standard of PTP1B-IN-1 (HY-10704). This product is intended for research and analytical applications. PTP1B-IN-1 (Compound 7a) is a small molecule inhibitor of PTP1B with an IC50 value of 1.6 mM. It is often used as the mother core for derivatives of analogues .
|
-
-
- HY-153018
-
|
|
Phosphatase
|
Metabolic Disease
|
|
PTP1B-IN-22, a ZINC02765569 derivative, is a potent protein tyrosine phosphatase 1B (PTP1B) inhibitor. PTP1B-IN-22 has PTP1B inhibition and glucose uptake in skeletal muscle L6 myotubes .
|
-
-
- HY-108196
-
|
|
Phosphatase
|
Endocrinology
|
|
PTP1B-IN-15 is a potent and selective inhibitor of protein tyrosine phosphatase 1B (PTP1B). PTP1B-IN-15 has the potential for the research of type II diabetes and obesity .
|
-
-
- HY-163463
-
|
|
Phosphatase
Fungal
HIV
Bacterial
|
Infection
Metabolic Disease
|
|
PTP1B-IN-25 (Compound 19) is a PTP1B inhibitor with remarkable antiviral, antibacterial, and antidiabetic activities. PTP1B-IN-25 has IC50 values of 0.37 μM, 8.6 μM, 3.7 μM, and 29 μM against PTP1B, HIV, α-Glucosidase, and methicillin-resistant Staphylococcus aureus (MRSA) respectively .
|
-
-
- HY-160550
-
|
|
Phosphatase
|
Inflammation/Immunology
|
|
DPM-1003 is a PTP1B conformational inhibitor that targets the non-catalytic, disordered segment at the C-terminus of the PTP1B protein, showing improvement in lung inflammation in mice .
|
-
-
- HY-156608
-
|
|
Phosphatase
|
Cancer
|
|
Anticancer agent 144 (compound 444) is a dual PTPN2/PTP1B inhibitor with IC50 values <2.5 nM. Anticancer agent 144 can be used in cancer research .
|
-
-
- HY-159694
-
|
ISIS 404173
|
Phosphatase
|
Metabolic Disease
|
|
IONIS PTP1BRx (ISIS 404173) is an antisense inhibitor of protein tyrosine phosphatase 1B (PTP-1B). IONIS PTP1BRx shows antidiabetic activity, and can be used for the study of insulin resistance and type 2 diabetes mellitus associated with obesity .
|
-
-
- HY-N16588
-
|
|
Phosphatase
|
Metabolic Disease
|
|
cis-Emodin-physcion bianthrone is a potent inhibitor of protein tyrosine phosphatase 1B (PTP1B), with an IC50 value of 7.29 μM. cis-Emodin-physcion bianthrone can be used for research on type 2 diabetes .
|
-
-
- HY-N8200
-
-
-
- HY-164425
-
|
|
Phosphatase
STAT
|
Metabolic Disease
|
|
ENT-03 is a centrally acting mammalian aminosterol. ENT-03 upregulates cFos activation, inhibits PTP1b and induces phosphorylation of STAT3. ENT-03 normalizes blood glucose, induces weight loss. ENT-03 can be used in the research of type 2 diabetes and obesity .
|
-
-
- HY-N3267
-
|
|
Phosphatase
|
Metabolic Disease
|
|
Methyl pseudolarate B, a natural diterpenoid, is a protein tyrosine phosphatase 1B (PTP1B) (Phosphatase) inhibitor with an IC50 value of 10.9 μM .
|
-
-
- HY-162499
-
|
|
Phosphatase
|
Metabolic Disease
|
|
MY17 is an inhibitor of protein tyrosine phosphatase 1B (PTP1B) (IC50=0.41±0.05 μM). MY17 alleviates palmitic acid (PA) -induced insulin resistance by up-regulating the expression of phosphorylated insulin receptor substrate (IRS1) and protein kinase B (AKT). By binding with PTP1B, MY17 can inhibit the activity of PTP1B, thereby improving insulin signaling and having anti-diabetic activity. MY17 can be used in the study of type 2 diabetes .
|
-
-
- HY-N13199
-
|
|
Phosphatase
|
Metabolic Disease
|
|
3-O-Dihydro-p-coumaroyltohogenol is a PTP1B inhibitor (IC50=6.27 μM) with antidiabetic and antiobesity activities .
|
-
-
- HY-173165
-
|
3-O-(6-Bromo-D-mannosyl)-28-acylamino-n-caproate methyl oleanolic acid
|
Phosphatase
Apoptosis
|
Cancer
|
|
OA-Br-1 is an orally active and selective inhibitor of PTP1B with an IC50 value of 7.08 μM. OA-Br-1 induces apoptosis. OA-Br-1 has broad spectrum anti-proliferative activity against cancer cells, and plays an anti-breast cancer role through the PTP1B/PI3K/AKT signaling pathway both in vitro and in vivo .
|
-
-
- HY-15133A
-
|
|
Phosphatase
|
Metabolic Disease
Cancer
|
|
PTP1B-IN-3 diammonium is a potent and orally active PTP1B inhibitor with IC50s of 120 nM for both PTP1B and TCPTP. PTP1B-IN-3 diammonium has antidiabetic and anticancer effects .
|
-
-
- HY-162479
-
|
|
Phosphatase
Amyloid-β
|
Metabolic Disease
|
|
PTP1B-IN-26 (Compound 7a) is a derivative of phenylthiosemicarbazide‐phenoxy‐1,2,3‐triazole‐N‐phenylacetamide. PTP1B-IN-26 is an inhibitor of protein tyrosine phosphatase 1B (PTP-1B). PTP1B-IN-26 is a competitive inhibitor. PTP1B-IN-26 can be used to research in type 2 diabetes .
|
-
-
- HY-179285
-
|
|
Phosphatase
|
Metabolic Disease
|
|
PTP1B-IN-32 (Compound 5G) is an uncompetitive PTP1B inhibitor, with a Ki value of 0.72 μM. PTP1B-IN-32 enhances insulin sensitivity. PTP1B-IN-32 can be used in the research of diabetes .
|
-
-
- HY-174250
-
|
|
Phosphatase
|
Inflammation/Immunology
Cancer
|
|
PTP1B-IN-31 (Compound (S,S)-3ak) is a PTP1B inhibitor with an IC50 of 0.81 μM. PTP1B-IN-31 can inhibit the growth of tumor cells in synergy with the cytokine IFNγ. PTP1B-IN-31 can be used in cancer research .
|
-
- HY-171027
-
|
|
Ligands for Target Protein for PROTAC
|
Cancer
|
|
PTP1B/TC-PTP IN-1 is a PTP1B and TC-PTP dual inhibitor. PTP1B/TC-PTP IN-1 can be used as a target protein ligand for the synthesis of DU-14 (PTP1B/TC-PTP PROTAC) (HY-164864) .
|
-
- HY-139641
-
|
|
Phosphatase
|
Others
|
|
PTP1B-IN-14 is a selective PTP1B inhibitor (IC50 = 0.72 μM) targeting the allosteric site.
|
-
- HY-139640
-
|
|
Phosphatase
|
Others
|
|
PTP1B-IN-13 is a selective PTP1B inhibitor targeting the allosteric site with an IC50 value of 1.59 μM.
|
-
- HY-144717
-
|
|
Phosphatase
|
Metabolic Disease
|
|
PTP1B-IN-18 is an orally active complete mixed type protein tyrosine phosphatase 1B (PTP1B) inhibitor with a Ki of 35.2 μM. PTP1B-IN-18 can be used for type 2 diabetes research .
|
-
- HY-144718
-
|
|
Phosphatase
|
Metabolic Disease
|
|
PTP1B-IN-17 (Compound 45), a potential selective benzimidazole derivative, acts as a protein tyrosine phosphatase 1B (PTP1B) inhibitor with a Ki of 30.2 μM. PTP1B-IN-17 can be used for the research of type 2 diabetes.
|
-
- HY-144716
-
|
|
Phosphatase
|
Metabolic Disease
|
|
PTP1B-IN-19 (Compound 43), a potential selective benzimidazole derivative, acts as a protein tyrosine phosphatase 1B (PTP1B) inhibitor with a Ki of 23.3 μM. PTP1B-IN-19 can be used for the research of type 2 diabetes.
|
-
- HY-144713
-
|
|
Phosphatase
|
Metabolic Disease
|
|
PTP1B-IN-16 (Compound 46), a potential selective benzimidazole derivative, acts as a protein tyrosine phosphatase 1B (PTP1B) inhibitor with a Ki of 12.6 μM. PTP1B-IN-16 can be used for the research of type 2 diabetes.
|
-
- HY-168185
-
|
|
Glycosidase
Phosphatase
Amylases
|
Metabolic Disease
|
|
α-glucosidase/PTP1B-IN-1 (compound 8a) is a potent α-glucosidase and PTP1B inhibitor with an IC50 value of 66.3 μM and 47.0 μM, respectively. α-glucosidase/PTP1B-IN-1 exhibits excellent activities against α-amylase with an IC50 of 30.62 μM. α-glucosidase/PTP1B-IN-1 can dock into the active pockets of α-glucosidase and PTP1B. α-glucosidase/PTP1B-IN-1 has potential to reduce the postprandial blood glucose and is used for Type 2 diabetes mellitus .
|
-
- HY-173034
-
|
|
Phosphatase
Apoptosis
|
Cancer
|
|
PTP1B-IN-30 (Compound 3j) is the inhibitor for PTP1B with an IC50 of 0.51 µM. PTP1B-IN-30 inhibits the proliferation of cancer cell T47D with an IC50 of 21.21 µM, arrests the cell cycle at S phase, and induces apoptosis in T47D .
|
-
- HY-170582
-
|
|
Phosphatase
|
Metabolic Disease
|
|
PTP1B-IN-29 (Compound A2B5) is an inhibitor for phosphatase, that inhibits protein tyrosine phosphatase 1B (PTP1B), TCPTP and λPPase with IC50s of 1.27 μM, 4.38 μM and 8.79 μM, respectively. PTP1B-IN-29 can be used in research of diabete and obesity .
|
-
- HY-149255
-
|
|
Phosphatase
Aldose Reductase
|
Metabolic Disease
|
|
PTP1B/AKR1B1-IN-2 (Compound 7f) is a dual PTP1B/AKR1B1 inhibitor (IC50s: 3.2 and 2.1 μM, Kis: 4.0 and 0.9μM). PTP1B/AKR1B1-IN-2 is an insulin-mimetic agent. PTP1B/AKR1B1-IN-2 improves glucose uptake in murine C2C12 myoblasts. PTP1B/AKR1B1-IN-2 can be used for research of Type 2 diabetes mellitus (T2DM) .
|
-
- HY-N10378
-
|
|
Phosphatase
|
Neurological Disease
Metabolic Disease
|
|
Rubrofusarin 6-O-β-D-glucopyranoside, the glycoside of Rubrofusarin, is a protein tyrosine phosphatase 1B (PTP1B) inhibitor with the IC50 of 87.36 μM. Rubrofusarin 6-O-β-D-glucopyranoside can be used for the research of comorbid diabetes and depression .
|
-
- HY-149254
-
|
|
Phosphatase
Aldose Reductase
|
Metabolic Disease
|
|
PTP1B/AKR1B1-IN-1 is a dual inhibitor of protein tyrosine phosphatase 1B (PTP1B) and aldose reductase (AKR1B1), with IC50s of 0.06 μM and 4.3 μM, respectively. PTP1B/AKR1B1-IN-1 also inhibits TC-PTP with an IC50 value of 9 μM. PTP1B/AKR1B1-IN-1 serves as an insulin-mimetic agent in murine myoblasts, and reduces AKR1B1-dependent sorbitol accumulation. PTP1B/AKR1B1-IN-1 inhibits development of type 2 diabetes mellitus (T2DM) to control blood glucose levels .
|
-
- HY-162480
-
|
|
Glycosidase
Phosphatase
|
Endocrinology
|
PTP1B-IN-27 (Compound 7i) is an inhibitor of protein tyrosine phosphatase 1-B (PTP‐1B)(IC50=8.2 µM). PTP1B-IN-27 also inhibits α-Glucosidase (IC50=120 µM) and shows competitive inhibition (Ki=118 µM) .
|
-
- HY-12312A
-
-
- HY-125108
-
-
- HY-131549A
-
|
|
PTEN
Phosphatase
|
Others
|
|
bpV(bipy) hydrate is the inhibitor for phosphoinositide 3-phosphatase (PTEN) and protein tyrosine phosphatases (PTP-β and PTP-1B) with IC50s of 18, 60.3, and 164 nM, respectively .
|
-
- HY-N10648
-
|
|
Phosphatase
|
Metabolic Disease
|
|
PTP1B-IN-20 is a selective inhibitor of protein tyrosine phosphatase 1B (PTP1B; IC50=1.05 μM) over the highly homologous T-cell protein tyrosine phosphatase (TCPTP; IC50=78.0 μM), which is a key target for type 2 diabetes inhibition .
|
-
- HY-156607
-
|
|
Phosphatase
|
Cancer
|
|
Anticancer agent 143 (compound 369) is a dual PTPN2/PTP1B inhibitor with IC50 values <2.5 nM. Anticancer agent 143 can be used in cancer research .
|
-
- HY-117830
-
|
|
Phosphatase
|
Endocrinology
|
|
CX08005 is a competitive PTP1B inhibitor. CX08005 can directly enhance the action of insulin in vivo and in vitro and improve insulin resistance .
|
-
- HY-N1783
-
|
|
Phosphatase
|
Cancer
|
|
(24E)-3,4-Secocucurbita-4,24-diene-3,26,29-trioic acid is a potent PTP1B inhibitor, with an IC50 of 0.4 μM. (24E)-3,4-Secocucurbita-4,24-diene-3,26,29-trioic acid exhibits potent PTP1B inhibitory activity without cytotoxicity .
|
-
- HY-N12736
-
|
|
Phosphatase
|
Metabolic Disease
|
|
Dehydrodanshenol A is a non-competitive inhibitor of Protein tyrosine phosphatase 1B (PTP1B), with an IC50 value of 8.5 μM. Dehydrodanshenol A can be used in diabetes-related research .
|
-
- HY-159694A
-
|
ISIS 404173 sodium
|
Phosphatase
|
Metabolic Disease
|
|
IONIS PTP1BRx (ISIS 404173) sodium is an antisense inhibitor of protein tyrosine phosphatase 1B (PTP-1B). IONIS PTP1BRx sodium shows antidiabetic activity, and can be used for the study of insulin resistance and type 2 diabetes mellitus associated with obesity .
|
-
- HY-N16415
-
|
|
Phosphatase
|
Inflammation/Immunology
|
|
Deoxyfunicone is a secondary fungal metabolite that inhibits PTP1B activity by binding to the active site of the enzyme with an IC50 value of 24.3µM. Deoxyfunicone has anti-inflammatory activity .
|
-
- HY-N15308
-
|
|
Phosphatase
|
Neurological Disease
Metabolic Disease
|
|
Kanjone is a compound found in Millettia peguensis and can be used for the synthesis of protein tyrosine phosphatase 1B (PTP1B) inhibitors. Kanjone holds promise for research in the fields of diabetes and neurological disorders .
|
-
- HY-128978
-
|
|
Phosphatase
|
Metabolic Disease
|
|
(E,E)-RAMB4 is a potent and selective potent protein tyrosine phosphatase-1B (PTP1B) inhibitor extracted from patent CN103626692A, example 1 .
|
-
- HY-N12354
-
|
|
Phosphatase
|
Metabolic Disease
|
|
Stevisaliosides D (Compound 5) can be isolated from Stevia serrata roots. Stevisaliosides D inhibits PTP1B (IC50: 31.8 μM). Stevisalioside D can be used for antidiabetic research .
|
-
- HY-155961
-
-
- HY-N16508
-
|
3-Hydroxyphlorizin
|
Phosphatase
|
Metabolic Disease
|
|
3-Hydroxyphloridzin (3-Hydroxyphlorizin) is a protein tyrosine phosphatase 1B (PTP1B) inhibitor. 3-Hydroxyphloridzin modulates insulin receptor phosphorylation levels. 3-Hydroxyphloridzin is promising for research of type 2 diabetes .
|
-
- HY-N12621
-
|
|
Phosphatase
|
Metabolic Disease
|
|
Antifungal agent 91(compound 1) is a dihydroflavonol that can be isolated from the leaves of Artocarpus elasticus. Antifungal agent 91 is a PTP1B inhibitor with an IC50 value of 0.17 μM. Antifungal agent 91 has antifungal activity .
|
-
- HY-123966A
-
|
|
Phosphatase
|
Neurological Disease
|
|
MY33-3 hydrochloride is a potent and selective inhibitor of receptor protein tyrosine phosphatase (RPTP)β/ζ, with an IC50 of ~0.1 μM. MY33-3 hydrochloride also inhibits PTP-1B (IC50 ~0.7 μM). MY33-3 hydrochloride can reduce ethanol consumption and alleviate Sevoflurane-induced neuroinflammation and cognitive dysfunction .
|
-
- HY-168706
-
|
|
Phosphatase
|
Metabolic Disease
|
|
LXQ-87 is an oral noncompetitive inhibitor of PTP1B with an IC50 of 1.061 μM, showing hypoglycemic activity. LXQ-87 alleviates insulin resistance and promotes cellular glucose uptake, making it useful for research on type 2 diabetes .
|
-
- HY-N7599
-
|
|
Phosphatase
Glycosidase
|
Metabolic Disease
|
|
Chrysophanol triglucoside is an anthraquinone isolated from Cassia obtusifolia, inhibits protein tyrosine phosphatases 1B (PTP1B) and α-glucosidase with IC50s of 80.17 and 197.06 µM, respectively. Chrysophanol triglucoside has the potential for diabetes research .
|
-
- HY-135564B
-
|
|
Phosphatase
|
Cancer
|
|
(Rac)-RK-682, a racemate of RK-682, is a protein tyrosine phosphatases (PTPases) inhibitor. (Rac)-RK-682 inhibits protein tyrosine phosphatase 1B (PTP-1B), low molecular weight protein tyrosine phosphatases (LMW-PTP), and cell division cycle 25B (CDC-25B) with IC50s of 8.6 μM, 12.4 μM, and 0.7 μM, respectively .
|
-
- HY-N12915
-
|
|
SHP2
Phosphatase
|
Metabolic Disease
Cancer
|
|
SHP2-IN-29 (Compound 3) is a potent SHP2 inhibitor with an IC50 value of 0.18 μM. SHP2-IN-29 also has inhibitory activity against PTP1B and TCPTP, with IC50 values of 4.27 and 4.74 μM, respectively.
|
-
- HY-163899
-
|
|
Phosphatase
|
Metabolic Disease
|
|
(+)-Crinatusin A1 (Compound (+)- 4) is a chalcone-monoterpene hybrid, which can be isolated from Cleistocalyx operculatus. (+)-Crinatusin A1 is an inhibitor for protein tyrosine phosphatase 1B (PTP1B) with IC50 of 0.9 μM. (+)-Crinatusin A1 exhibits potential as an antidiabetic agent .
|
-
- HY-N12761
-
|
|
Phosphatase
Glycosidase
|
Metabolic Disease
Inflammation/Immunology
|
|
Penpaxilloids A (Compound 1) is a non-competitive inhibitor of protein tyrosine phosphatase 1B (PTP1B) with an IC50 value of 8.60 μM. Penpaxilloids A can be isolated from the fungus Penicillium sp. ZYX-Z-143. Penpaxilloids A is also an α-glucosidase (α-glucosidase) inhibitor with anti-inflammatory activity .
|
-
- HY-160514
-
|
|
Phosphatase
|
Metabolic Disease
|
|
LXQ46 is an orally active inhibitor for protein tyrosine phosphatase 1B (PTP1B), with an IC50 of 0.190 μM. LXQ46 enhances insulin and leptin signaling pathways in insulin-resistant C2C12. LXQ46 ameliorates type 2 diabetes and increases insulin tolerance in mouse models .
|
-
- HY-181239
-
|
|
Phosphatase
|
Inflammation/Immunology
Cancer
|
|
PTP1B-IN-33 is a PTP1B inhibitor with a human IC50 of 2.45 μM and over 20-fold selectivity for PTP1B over SHP2. PTP1B-IN-33 enhances π-Alkyl interaction with PTP1B to increase WPD loop closure degree. PTP1B-IN-33 can be used for the research of cancer, diabetes, autoimmune deficiency diseases .
|
-
- HY-108196R
-
|
|
Reference Standards
Phosphatase
|
Endocrinology
|
|
PTP1B-IN-15 (Standard) is the analytical standard of PTP1B-IN-15 (HY-108196). This product is intended for research and analytical applications. PTP1B-IN-15 is a potent and selective inhibitor of protein tyrosine phosphatase 1B (PTP1B). PTP1B-IN-15 has the potential for the research of type II diabetes and obesity .
|
-
- HY-181700
-
|
|
Phosphatase
GLUT
|
Metabolic Disease
|
|
PTP1B-IN-34 is an orally active, selective, non-competitive PTP1B inhibitor, with an IC50 value of 0.64 μM and a Ki value of 1.15 μM against human PTP1B. PTP1B-IN-34 reduces blood glucose levels in diabetic mice. PTP1B-IN-34 can be used in research related to type 2 diabetes .
|
-
- HY-100462R
-
|
|
Phosphatase
Reference Standards
|
Metabolic Disease
|
|
PTP1B-IN-2 (Standard) is the analytical standard of PTP1B-IN-2 (HY-100462). This product is intended for research and analytical applications. PTP1B-IN-2 is a potent protein tyrosine phosphatase 1B (PTP1B) inhibitor with an IC50 of 50 nM.
|
-
- HY-N17424
-
|
|
Phosphatase
|
Inflammation/Immunology
|
|
Mulberrofuran D is a protein tyrosine phosphatase 1B (PTP1B) inhibitor, with an IC50 of 11.61 μM and a Ki of 4.79 μM against human PTP1B. Mulberrofuran D can be used in research related to type 2 diabetes .
|
-
- HY-182483
-
|
|
Phosphatase
|
Metabolic Disease
|
|
Ethyl-3,4-dephostatin is a Protein tyrosine phosphatase 1B (PTP1B) inhibitor with an IC50 of 0.58 μg/mL. Ethyl-3,4-dephostatin can be used in studies of PTP1B-related enzyme inhibition mechanisms .
|
-
- HY-N14540
-
|
|
Phosphatase
Akt
|
Cancer
|
|
Glycybenzofuran is a flavonoid. Glycybenzofuran can be isolated from G. uralensis. Glycybenzofuran is a potent, competitive, selective PTP1B inhibitor. Glycybenzofuran shows excellent inhibitory selectivity against PTP1B. Glycybenzofuran increases insulin-stimulated pAkt levels. Glycylbenzofuran can be used in the research of hepatocellular carcinoma .
|
-
- HY-N17455
-
-
- HY-N17326
-
|
|
Acyltransferase
Phosphatase
Interleukin Related
|
Metabolic Disease
Inflammation/Immunology
|
|
Ilekudinol B is an inhibitor of ACAT and PTP1B, with an IC50 of 5.3 μM and a Ki of 11.6 μM against human PTP1B. Ilekudinol B inhibits the classical pathway of the complement system, with an IC50 of 51 μM. Ilekudinol B inhibits TNF-α-induced cellular IL-8 secretion, promotes glucose uptake in skeletal muscle myotubes, and acts as an insulin mimetic and insulin sensitizer. Ilekudinol B can be used in research related to type 2 diabetes, obesity, and inflammatory diseases .
|
-
- HY-N17642
-
|
|
Phosphatase
|
Metabolic Disease
|
|
Arhododendric acid A (Compound 1) is a triterpenoid found in Rhododendron brachycarpum. Arhododendric acid A can inhibit PTP1B with an IC50 of 6.3 μM. Arhododendric acid A can be used for the research of type 2 diabetes .
|
-
- HY-N16588A
-
|
|
Phosphatase
|
Metabolic Disease
|
|
trans-Emodin-physcion bianthrone is a protein tyrosine phosphatase 1B (PTP1B) inhibitor with an IC50 of 2.77 μM. trans-Emodin-physcion bianthrone is applicable to research related to insulin resistance .
|
-
- HY-N18297
-
|
|
Phosphatase
|
Metabolic Disease
|
|
Licoagrochalcone A is a PTP1B inhibitor. Licoagrochalcone A exerts protective effects against liver cell injury induced by carbon tetrachloride and Acetaminophen (HY-66005). Licoagrochalcone A is applicable to the research of type 2 diabetes, obesity and liver injury .
|
-
- HY-N17601
-
|
|
Phosphatase
Glycosidase
|
Metabolic Disease
|
|
Parvisoflavone B is a prenylated flavonoid. Parvisoflavone B can be isolated from root bark of Erythrina mildbraedii. Parvisoflavone B inhibits PTP1B activity with an IC50 of 42.6 μM. Parvisoflavone B inhibits α-glucosidase with an IC50 of 12.19 μM. Parvisoflavone B can be used in the research of type 2 diabetes and obesity .
|
-
- HY-182463
-
|
|
Phosphatase
|
Metabolic Disease
Inflammation/Immunology
Cancer
|
|
Moreollic acid is a PTP1B inhibitor, with an IC50 of 4.44 μM and a Ki of 1.75 μM against human targets. Moreollic acid blocks cell cycle progression from the G1 to S phase and inhibits tumor cell proliferation. Moreollic acid can be used in research related to type 2 diabetes, obesity, colon cancer and other cancers .
|
-
- HY-N13813
-
|
|
Phosphatase
Glycosidase
|
Others
|
|
Ethyl-3,5-di-O-caffeoylquinate is an ethyl caffeoylquinate (ECQ), and ECQ analogs are potential α-glucosidase (α-glucosidase) inhibitors and PTP1B inhibitors. Ethyl-3,5-di-O-caffeoylquinate, which can be isolated from the flower buds of Lonicera macranthoides, is an isomer of chlorogenic acid (ethyl dicaffeoylquinate) .
|
-
- HY-118567
-
|
BMOV
|
SHP2
Phosphatase
|
Metabolic Disease
|
|
Bis(maltolato)oxovanadium(IV) (BMOV) is a potent, reversible, competitive and orally active pan-PTP (protein tyrosine phosphatases) inhibitor. Bis(maltolato)oxovanadium(IV) inhibits HCPTPA, PTP1B, HPTPβ and SHP2 with IC50s of 126 nM, 109 nM, 26 nM and 201 nM, respectively. Bis(maltolato)oxovanadium(IV) is a potent insulin sensitizer .
|
-
- HY-120159
-
|
|
SHP2
SHP1
Phosphatase
|
Cancer
|
|
GS-493 is a selective protein tyrosine phosphatase SHP2 (PTPN11) inhibitor with an IC50 of 71 nM. GS-493 is 29- and 45-fold more active toward SHP2 than related SHP1 and PTP1B. GS-493 blocks cellular motility and growth of cancer cells. Antitumor activity .
|
-
- HY-N7165
-
|
|
Phosphatase
Bacterial
|
Infection
Metabolic Disease
|
|
3-O-cis-p-Coumaroyl maslinic acid (compound 16) is a natural compound isolated from the ethyl acetate extract of leaves of Miconia albicans.3-O-cis-p-Coumaroyl maslinic acid can inhibit PTP1B, with the IC50 of 0.46 μM, and shows antimicrobial activity on Gram-positive bacteria and yeasts .
|
-
- HY-181683
-
|
|
|
Metabolic Disease
|
|
Antidiabetic agent 8 is an orally active multi-target inhibitor, with IC50 values of 9.79, 6.36 and 19.08 μM against α-glucosidase, α-amylase and PTP1B, respectively. Antidiabetic agent 8 reduces postprandial blood glucose elevation. Antidiabetic agent 8 can be used in the research of type 2 diabetes .
|
-
- HY-124896
-
|
6-Geranylnaringenin; Mimulone
|
Phosphatase
Apoptosis
Autophagy
|
Inflammation/Immunology
Cancer
|
|
Bonannione A (6-Geranylnaringenin; Mimulone), a prenylflavonoid, is an orally active and potent protein tyrosine phosphatase 1B (PTP1B) inhibitor with an IC50 of 14 µM. Bonannione A triggers caspase-dependent apoptosis. Bonannione A induces autophagy through p53-mediated AMPK/mTOR pathway. Bonannione A shows anti-inflammatory, antiradical and anti-cancer activity .
|
-
- HY-138964
-
|
|
Phosphatase
|
Cancer
|
|
TC-PTP-IN-1 (compound 8) is a potent TC-PTP inhibitor with an IC50 value of 9.2 nM, Ki values of 4.3, 34 nM for TC-PTP, PTP1B, respectively. TC-PTP-IN-1 increases the protein expression of pSre416 . TC-PTP-IN-1 (compound 3) is the TC-PTP Ligand of TP1L (HY-160151) .
|
-
- HY-155558
-
|
|
Antibiotic
|
Infection
|
|
MptpB-IN-2 (compound 20) is a selective mycobacterium tuberculosis protein tyrosine phosphatase B (MptpB) inhibitor with IC50s of 0.64 μM, 4.06 μM and 4.14 μM for MptpB, MptpA and PTP1B, respectively. MptpB-IN-2 shows weak antituberculosis activity with a MIC of 64.9 μM for Mtb H37Rv .
|
-
- HY-N0621
-
-
- HY-N1117
-
|
|
Phosphatase
NO Synthase
|
Infection
Metabolic Disease
Cancer
|
|
Tristin is a PTP1B inhibitor (IC50=21.2 μM) with antioxidant and antifungal activities. Tristin inhibits lipid peroxidation and NO production in LPS-stimulated macrophages, and also exhibits activity against a variety of phytopathogenic fungi. Tristin is also able to inhibit cancer cell proliferation. Tristin can be used in the research of diseases associated with phytopathogenic fungal infection, leukemia, type 2 diabetes and inflammatory responses .
|
-
- HY-120327
-
KY-226
2 Publications Verification
|
Phosphatase
|
Neurological Disease
Metabolic Disease
|
|
KY-226 is a potent, selective, orally active and allosteric protein tyrosine phosphatase 1B (PTP1B) inhibitor with an IC50 of 0.25 μM, and without PPARγ agonist activity. KY-226 exerts anti-diabetic and anti-obesity effects by enhancing insulin and leptin signaling, respectively. KY-226 also protects neurons from cerebral ischemic injury .
|
-
- HY-W002314
-
|
|
Environmental Pollutants
Drug Intermediate
Phosphatase
|
Cardiovascular Disease
|
|
2-Bromo-4'-hydroxyacetophenone is a PTP1B inhibitor with a Ki value of 42 μM. 2-Bromo-4'-hydroxyacetophenone is also an intermediate. 2-Bromo-4'-hydroxyacetophenone can be used in the synthesis of LXRα/β antagonists. 2-Bromo-4'-hydroxyacetophenone can be used in research on hematological diseases .
|
-
- HY-136065
-
|
|
PTEN
Phosphatase
Parasite
Apoptosis
|
Infection
Metabolic Disease
Inflammation/Immunology
Cancer
|
|
bpV(phen), a insulin-mimetic agent, is a potent protein tyrosine phosphatase (PTP) and PTEN inhibitor with IC50s of 38 nM, 343 nM and 920 nM for PTEN, PTP-β and PTP-1B, respectively. bpV(phen) inhibits proliferation of the protozoan parasite Leishmania in vitro. bpV(phen) strongly induces the secretion of a large number of chemokines and pro-inflammatory cytokines, and it activates a Th1-type pathway (IL-12, IFNγ). bpV(phen) can also induce cell apoptosis, and has anti-angiogenic and anti-tumor activity .
|
-
- HY-N1941
-
-
- HY-122818
-
|
Bisperoxovanadium(phen) trihydrate
|
PTEN
Phosphatase
Parasite
Apoptosis
|
Infection
Metabolic Disease
Inflammation/Immunology
Cancer
|
|
BpV(phen) trihydrate, a insulin-mimetic agent, is a potent protein tyrosine phosphatase (PTP) and PTEN inhibitor with IC50s of 38 nM, 343 nM and 920 nM for PTEN, PTP-β and PTP-1B, respectively. BpV(phen) trihydrate inhibits proliferation of the protozoan parasite Leishmania in vitro. bpV(phen) trihydrate strongly induces the secretion of a large number of chemokines and pro-inflammatory cytokines, and it activates a Th1-type pathway (IL-12, IFNγ). BpV(phen) trihydrate can also induce cell apoptosis, and has anti-angiogenic and anti-tumor activity .
|
-
- HY-118529
-
|
|
Phosphatase
|
Cancer
|
|
JUN-1111 is an irreversible and selective Cdc25 phosphatase inhibitor with IC50 values of 0.38, 1.8, 0.66, 28, 37 µM for Cdc25A, Cdc25B, Cdc25C, VHR, PTP1B, respectively. JUN-1111 induces cell cycle arrest at G1 and G2/M phases. JUN-1111 decreases the expression of phosphoCdk1 .
|
-
- HY-148922
-
|
|
PPAR
|
Metabolic Disease
|
|
PPARα/γ agonist 2 is an orally active PPARα full agonist and PPARγ partial agonist. PPARα/γ agonist 2 activates PPARα and PPARγ with EC50 values of 0.95 μM and 0.91 μM respectively. PPARα/γ agonist 2 is also a PTP1B inhibitor. PPARα/γ agonist 2 is an anti-diabetic agent .
|
-
- HY-179380
-
|
|
Phosphatase
IFNAR
JAK
STAT
|
Cancer
|
|
PTPN2-IN-2 is a potent and orally active PTPN2 inhibitor (IC50 = 7.05 nM) that enhances the IFN-γ signaling pathway. PTPN2-IN-2 inhibits PTP1B with an IC50 of 9.88 nM. PTPN2-IN-2 inhibits tumor growth, promotes the activation and infiltration of tumor immune cells in a B16-OVA mouse model. PTPN2-IN-2 can be used for the research of melanoma .
|
-
- HY-112478
-
|
|
Phosphatase
SHP2
|
Cancer
|
|
PTP Inhibitor IV is a protein tyrosine phosphatase (PTP) inhibitor that competitively inhibits DUSP14 phosphatase activity with an 50 of 5.21 μM . PTP Inhibitor IV inhibits SHP-2, PTP1B, PTP-ε, PTP Meg-2, PTP-σ, PTP-β, and PTP-μ with 50s of 1.8 μM, 2.5 μM, 8.4 μM, 13 μM, 20 μM, 6.4 μM, and 6.7 μM, respectively .
|
-
- HY-N2217
-
-
- HY-N0646
-
|
|
Phosphatase
Endogenous Metabolite
Tyrosinase
Apoptosis
Interleukin Related
|
Inflammation/Immunology
Cancer
|
|
Silydianin is a flavonolignan. Silydianin can be obtained from Silybum marianum. Silydianin inhibits PTP1B with an IC50 of 17.38 μM. Silydianin inhibits both monophenolase and diphenolase of tyrosinase significantly, with IC50s of 2.6 μM and 16.5 μM, respectively. Silydianin induces Apoptosis and reduces cytokines (IL-4 and IL-5). Silymarin has antioxidant, cytoprotective and immunomodulatory effects. Silydianin has antitumor activity against prostate cancer. Silymarin can be used in allergic asthma research .
|
-
- HY-178297
-
|
|
Phosphatase
|
Cancer
|
|
VHR-IN-7 is a selective vaccinia H1-related (VHR) phosphatase inhibitor with an IC50 of 71 nM. VHR-IN-7 shows very weaker inhibitory activity against MKP-1 (IC50 = 0.47 μM), CD45 (IC50 = 0.3 μM), Cdc25A (IC50 = 3.4 μM), PTP1B (IC50 = 0.59 μM), and HePTP (IC50 = 1.2 μM). VHR-IN-7 inhibits the proliferation of HeLa cells. VHR-IN-7 can be used for the research of cervical cancer .
|
-
- HY-178296
-
|
|
Phosphatase
|
Cancer
|
|
VHR-IN-6 is a selective vaccinia H1-related (VHR) phosphatase inhibitor with an IC50 of 74 nM. VHR-IN-6 shows very weaker inhibitory activity against MKP-1 (IC50 = 0.52 μM), CD45 (IC50 = 0.50 μM), Cdc25A (IC50 = 2.8 μM), PTP1B (IC50 = 0.42 μM), and HePTP (IC50 = 0.87 μM). VHR-IN-6 inhibits the proliferation of HeLa cells. VHR-IN-6 can be used for the research of cervical cancer .
|
-
- HY-N19818
-
|
|
Phosphatase
NF-κB
Pregnane X Receptor (PXR)
|
Cancer
|
|
Glycybridin C is a Protein tyrosine phosphatase 1B (PTP1B) inhibitor and pregnane X receptor (PXR) ligand. Glycybridin C inhibits insulin and leptin signaling pathway negative regulation, LPS (HY-D1056)-induced NF-κB transcriptional activity. Glycybridin C forms hydrophobic and π-π stacking interactions with Met243, Phe288, Tyr306, and His407 residues of PXR. Glycybridin C can be used for the research of hepatocellular carcinoma, colorectal adenocarcinoma, breast carcinoma .
|
-
- HY-178301
-
|
|
Phosphatase
|
Cancer
|
|
VHR-IN-9 is a selective vaccinia H1-related (VHR) phosphatase inhibitor with an IC50 of 270 nM. VHR-IN-9 shows very weaker inhibitory activity against MKP-1 (IC50 = 2.8 μM), CD45 (IC50 = 1.8 μM), Cdc25A (IC50 = > 10 μM), PTP1B (IC50 = 2.2 μM), and HePTP (IC50 = 2.4 μM). VHR-IN-9 inhibits the proliferation of HeLa cells. VHR-IN-9 can be used for the research of cervical cancer .
|
-
- HY-178295
-
|
|
Phosphatase
|
Cancer
|
|
VHR-IN-5 is a selective vaccinia H1-related (VHR) phosphatase inhibitor with an IC50 of 78 nM. VHR-IN-5 shows very weaker inhibitory activity against MKP-1 (IC50 = 0.78 μM), CD45 (IC50 = 0.61 μM), Cdc25A (IC50 = 3.4 μM), PTP1B (IC50 = 1.8 μM), and HePTP (IC50 = 1.5 μM). VHR-IN-5 inhibits the proliferation of HeLa cells. VHR-IN-5 can be used for the research of cervical cancer .
|
-
- HY-116474
-
|
|
ERK
JNK
MMP
p38 MAPK
STAT
Fungal
Bacterial
NO Synthase
PGE synthase
NF-κB
Wnt
β-catenin
|
Infection
Metabolic Disease
Inflammation/Immunology
|
|
Viridicatol is a quinolone alkaloid with anti-inflammatory, antibacterial, antifungal, osteogenic and chondrogenic activities. Viridicatol reduces the phosphorylation levels of ERK, JNK, p38 and STAT6; inhibits MMP-2, MMP-9, NF-κB signaling pathway and PTP1B; downregulates genes related to mast cell activation; and binds to SHN3 to activate the Wnt/SHN3 signaling pathway. Viridicatol inhibits the expression of pro-inflammatory mediators and cytokines, and promotes osteogenic/chondrogenic differentiation. Viridicatol can be used in studies related to fibrosarcoma, allergy, bacterial infection, fungal infection and osteoporosis .
|
-
- HY-N6651
-
|
|
STAT
Phosphatase
Apoptosis
Autophagy
p38 MAPK
EGFR
JAK
Bcl-2 Family
Survivin
Akt
mTOR
PARP
Caspase
Atg8/LC3
CDK
|
Cancer
|
|
Isocryptotanshinone is a dual STAT3 and PTP1B (IC50 = 56.1 μM) inhibitor. Isocryptotanshinone inhibits STAT3 by binding to the STAT3 SH2 domain to block phosphorylation and nuclear translocation [1][2]. Isocryptotanshinone exerts its anti-proliferative effect via the induction of cell cycle arrest, apoptosis, and pro-death autophagy, through the regulation of STAT3, AKT/mTOR and MAPK signaling pathways. Isocryptotanshinone suppresses the xenograft gastric cancer (GC) tumor growth in BALB/c nude mice. Isocryptotanshinone can be used for cancer research, such as lung cancer, breast cancer and GC .
|
-
- HY-109041A
-
|
AKB-9778 sodium
|
Phosphatase
Tie
|
Inflammation/Immunology
|
|
Razuprotafib (AKB-9778) sodium is a potent and selective inhibitor of the catalytic activity of VE-PTP (vascular endothelial protein tyrosine phosphatase) with an IC50of 17 pM. Razuprotafib sodium promotes TIE2 activation, enhances ANG1-induced TIE2 activation, and stimulates phosphorylation of signaling molecules in the TIE2 pathway, including AKT, eNOS, and ERK. Razuprotafib sodium inhibits the structurally related phosphatase PTP1B with an IC50 of 780 nM. Razuprotafib sodium shows excellent selectivity for VE-PTP versus a variety of phosphatases, with the exception of HPTPη (IC50=36 pM) and HPTPγ (100 pM) .
|
-
- HY-183573
-
|
|
Phosphatase
Toll-like Receptor (TLR)
NF-κB
Interleukin Related
|
Inflammation/Immunology
|
|
PTPRO-IN-1 is a selective, orally active PTPRO inhibitor with an IC50 of 0.16 μM. PTPRO-IN-1 exhibits IC50 values of 2.4 μM, 2.33 μM and 2.13 μM against PTPN22, PTP1B and PTPRT, respectively, and shows almost no inhibitory activity against STEP/SSH2. PTPRO-IN-1 inhibits the TLR4/NF-κB signaling pathway in macrophages, ameliorates colonic pathological conditions and suppresses the secretion of pro-inflammatory cytokines by T cells. PTPRO-IN-1 can be used for the research of inflammatory bowel disease .
|
-
- HY-109041
-
|
AKB-9778
|
Phosphatase
Tie
|
Inflammation/Immunology
|
|
Razuprotafib (AKB-9778) is a potent and selective inhibitor of the catalytic activity of VE-PTP (vascular endothelial protein tyrosine phosphatase) with an IC50of 17 pM. Razuprotafib promotes TIE2 activation, enhances ANG1-induced TIE2 activation, and stimulates phosphorylation of signaling molecules in the TIE2 pathway, including AKT, eNOS, and ERK. Razuprotafib inhibits the structurally related phosphatase PTP1B with an IC50 of 780 nM. Razuprotafib shows excellent selectivity for VE-PTP versus a variety of phosphatases, with the exception of HPTPη (IC50=36 pM) and HPTPγ (100 pM) .
|
-
- HY-N2217R
-
|
|
Reference Standards
Akt
mTOR
p38 MAPK
Apoptosis
|
Cardiovascular Disease
Inflammation/Immunology
Cancer
|
|
Rotundic acid (Standard) is the analytical standard of Rotundic acid (HY-N2217). This product is intended for research and analytical applications. Rotundic acid is an orally effective triterpenoid with a Kd value of 51.3 µM for PTP1B. Rotundic acid downregulates the AKT/mTOR pro-survival pathway and modulates the MAPK pathway. Rotundic acid induces cell cycle S-phase arrest, DNA damage and apoptosis; it inhibits migration, invasion, angiogenesis and proliferation of cancer cells. Rotundic acid improves leptin sensitivity, regulates gut microbiota and reduces cellular senescence. Rotundic acid can be used in research related to hepatocellular carcinoma, obesity, aging, acute lung injury and type 2 diabetes .
|
-
- HY-N0646R
-
|
|
Reference Standards
Phosphatase
Endogenous Metabolite
Tyrosinase
Apoptosis
Interleukin Related
|
Inflammation/Immunology
Cancer
|
|
Silydianin (Standard) is the analytical standard of Silydianin (HY-N0646). This product is intended for research and analytical applications. Silydianin is a flavonolignan. Silydianin can be obtained from Silybum marianum. Silydianin inhibits PTP1B with an IC50 of 17.38 μM. Silydianin inhibits both monophenolase and diphenolase of tyrosinase significantly, with IC50s of 2.6 μM and 16.5 μM, respectively. Silydianin induces Apoptosis and reduces cytokines (IL-4 and IL-5). Silymarin has antioxidant, cytoprotective and immunomodulatory effects. Silydianin has antitumor activity against prostate cancer. Silymarin can be used in allergic asthma research .
|
-
- HY-117085
-
|
|
Phosphatase
TMV
Lipoxygenase
|
Cancer
|
|
Lobaric acid is a depsipeptide metabolite isolated from Stereocaulon lichen with antioxidant, antiproliferative, antiviral and enzyme inhibitory activities. Lobaric acid scavenges superoxide free radicals (IC50=97.9 μM) and inhibits cancer cell proliferation (EC50 of 15.2-63.9 μg/mL against leukemia, colorectal, gastric, breast, ovarian, prostate, pancreatic and lung cancer cell lines). Lobaric acid inhibits protein tyrosine phosphatase 1B (PTP1B; IC50=0.87 μM for human recombinant enzyme) and 12(S)-HETE produced by 12(S)-lipoxygenase (IC50=28.5 μM). Lobaric acid (250 μM) also reduced pathological changes in tobacco leaves infected with tobacco mosaic virus (TMV).
|
-
- HY-174322
-
|
|
SHP2
ERK
Fluorescent Dye
|
Cancer
|
|
SHP2-IN-38 is a novel green-fluorescent SHP2 inhibitor with IC50 values of 2.89 μM (SHP2), 8.73 μM (SHP1), 11.08 μM (PTP1B), 33.07 μM (TCPTP). SHP2-IN-38 blocks the SHP2-mediated ERK signaling pathway and inhibits MV4-11 cells proliferation in vitro with IC50 of 7.90 μM. SHP2-IN-38 has an excitation wavelength of 360 nm, with a maximum emission wavelength of 550 nm in DMSO and 540 nm in DMF. SHP2-IN-38 shows green fluorescence imaging in HeLa cells and zebrafish.
|
-
- HY-116474R
-
|
|
Reference Standards
JNK
β-catenin
NO Synthase
PGE synthase
Fungal
STAT
ERK
MMP
p38 MAPK
Bacterial
NF-κB
Wnt
|
Infection
Metabolic Disease
Inflammation/Immunology
|
|
Viridicatol (Standard) is the analytical standard of Viridicatol (HY-116474). This product is intended for research and analytical applications. Viridicatol is a quinolone alkaloid with anti-inflammatory, antibacterial, antifungal, osteogenic and chondrogenic activities. Viridicatol reduces the phosphorylation levels of ERK, JNK, p38 and STAT6; inhibits MMP-2, MMP-9, NF-κB signaling pathway and PTP1B; downregulates genes related to mast cell activation; and binds to SHN3 to activate the Wnt/SHN3 signaling pathway. Viridicatol inhibits the expression of pro-inflammatory mediators and cytokines, and promotes osteogenic/chondrogenic differentiation. Viridicatol can be used in studies related to fibrosarcoma, allergy, bacterial infection, fungal infection and osteoporosis .
|
-
- HY-109041R
-
|
AKB-9778 (Standard)
|
Reference Standards
Phosphatase
Tie
|
Inflammation/Immunology
|
|
Razuprotafib (Standard) is the analytical standard of Razuprotafib (HY-109041). This product is intended for research and analytical applications. Razuprotafib (AKB-9778) is a potent and selective inhibitor of the catalytic activity of VE-PTP (vascular endothelial protein tyrosine phosphatase) with an IC50of 17 pM. Razuprotafib promotes TIE2 activation, enhances ANG1-induced TIE2 activation, and stimulates phosphorylation of signaling molecules in the TIE2 pathway, including AKT, eNOS, and ERK. Razuprotafib inhibits the structurally related phosphatase PTP1B with an IC50 of 780 nM. Razuprotafib shows excellent selectivity for VE-PTP versus a variety of phosphatases, with the exception of HPTPη (IC50=36 pM) and HPTPγ (100 pM) .
|
-
- HY-183801
-
|
|
Phosphatase
Apoptosis
|
Cancer
|
|
Cu2LCl2(H2O) acts as a proteasome inhibitor and protein tyrosine phosphatase inhibitor, with antiproliferative and apoptosis-inducing effects. Cu2LCl2(H2O) exhibits low cytotoxicity against normal cells and remarkable in vivo antitumor efficacy. Cu2LCl2(H2O) inhibits proteasome activity in colon cancer cells, and suppresses PTP1B and TCPTP activities in breast cancer cells. Cu2LCl2(H2O) can be used in the research of colon cancer, breast cancer and liver cancer .
|
-
- HY-155847
-
|
|
Phosphatase
PD-1/PD-L1
|
Inflammation/Immunology
Cancer
|
|
LYP-IN-3 is a selective, orally active and reversible lymphoid-tyrosine phosphatase (LYP) inhibitor (IC50 = 2.55 μM, Ki = 0.93 μM). D34 exhibits high selectivity of PTP1B, PTPN12, PTPN5 and SSH2. LYP-IN-3 regulates the T-cell receptor (TCR) signaling by specifically inhibiting LYP. LYP-IN-3 does not significantly inhibit MC38 cell viability; its anti-tumor effect stems from immune regulation. LYP-IN-3 can significantly upregulate PD-L1 or PD-1 expression in different immune cells. LYP-IN-3 facilitates T-cell infiltration and enhances T-cell functions. LYP-IN-3 synergizes with PD-L1 blockade can significantly improve colorectal tumor regression. LYP-IN-3 can be used for the study of colorectal cancer .
|
-
- HY-N3266
-
|
|
Tyrosinase
Phosphatase
Cholinesterase (ChE)
SARS-CoV
PERK
JNK
p38 MAPK
TGF-beta/Smad
Apoptosis
Reactive Oxygen Species (ROS)
AMPK
MMP
|
Cardiovascular Disease
Infection
Neurological Disease
Inflammation/Immunology
Cancer
|
|
Methyl rosmarinate is an orally active hydroxycinnamic acid. Methyl rosmarinate exhibits an IC50 of 24.70 μM and a Ki of 15.29 μM against PTP1B, an IC50 of 41.46 μg/mL against BChE, a Ki of 0.61 mM against mushroom tyrosinase, and an IC50 of 2.50 μM against SARS-CoV-2 3CLpro. Methyl rosmarinate downregulates the phosphorylation levels of ERK, JNK, p38, Smad2 and Smad3. Methyl rosmarinate activates erythrocyte BPGM and promotes the production of 2,3-BPG. Methyl rosmarinate induces apoptosis of fibroblasts. Methyl rosmarinate prolongs the survival time of hypoxic mice. Methyl rosmarinate improves insulin sensitivity. Methyl rosmarinate binds to SARS-CoV-2 3CLpro and inhibits viral replication. Methyl rosmarinate induces glioblastoma cell death. Methyl rosmarinate activates the TGR5/AMPK axis and reduces the levels of ROS and MDA. Methyl rosmarinate shows inhibitory activity against MMP-1. Methyl rosmarinate can be used in research related to pulmonary fibrosis, hypoxia-induced injury, type 2 diabetes, Alzheimer's disease, hyperpigmentation disorders, COVID-19, glioblastoma and myocardial ischemia-reperfusion injury .
|
-
| Cat. No. |
Product Name |
Category |
Target |
Chemical Structure |
-
- HY-N0621
-
-
-
- HY-N1549
-
-
-
- HY-N0646
-
-
-
- HY-N0374
-
-
-
- HY-N1941
-
-
-
- HY-N2217
-
-
-
- HY-N3266
-
|
|
Structural Classification
Classification of Application Fields
Simple Phenylpropanols
Adenocarpus cincinnatus (Ball) Maire
Labiatae
Phenols
Polyphenols
Phenylpropanoids
Plants
Disease Research Fields
Source Classification
Cancer
|
Tyrosinase
Phosphatase
Cholinesterase (ChE)
SARS-CoV
PERK
JNK
p38 MAPK
TGF-beta/Smad
Apoptosis
Reactive Oxygen Species (ROS)
AMPK
MMP
|
|
Methyl rosmarinate is an orally active hydroxycinnamic acid. Methyl rosmarinate exhibits an IC50 of 24.70 μM and a Ki of 15.29 μM against PTP1B, an IC50 of 41.46 μg/mL against BChE, a Ki of 0.61 mM against mushroom tyrosinase, and an IC50 of 2.50 μM against SARS-CoV-2 3CLpro. Methyl rosmarinate downregulates the phosphorylation levels of ERK, JNK, p38, Smad2 and Smad3. Methyl rosmarinate activates erythrocyte BPGM and promotes the production of 2,3-BPG. Methyl rosmarinate induces apoptosis of fibroblasts. Methyl rosmarinate prolongs the survival time of hypoxic mice. Methyl rosmarinate improves insulin sensitivity. Methyl rosmarinate binds to SARS-CoV-2 3CLpro and inhibits viral replication. Methyl rosmarinate induces glioblastoma cell death. Methyl rosmarinate activates the TGR5/AMPK axis and reduces the levels of ROS and MDA. Methyl rosmarinate shows inhibitory activity against MMP-1. Methyl rosmarinate can be used in research related to pulmonary fibrosis, hypoxia-induced injury, type 2 diabetes, Alzheimer's disease, hyperpigmentation disorders, COVID-19, glioblastoma and myocardial ischemia-reperfusion injury .
|
-
-
- HY-116474
-
|
|
Infection
Alkaloids
Structural Classification
Monophenols
Microorganisms
Classification of Application Fields
Phenols
Quinoline Alkaloids
Disease Research Fields
Source Classification
|
ERK
JNK
MMP
p38 MAPK
STAT
Fungal
Bacterial
NO Synthase
PGE synthase
NF-κB
Wnt
β-catenin
|
|
Viridicatol is a quinolone alkaloid with anti-inflammatory, antibacterial, antifungal, osteogenic and chondrogenic activities. Viridicatol reduces the phosphorylation levels of ERK, JNK, p38 and STAT6; inhibits MMP-2, MMP-9, NF-κB signaling pathway and PTP1B; downregulates genes related to mast cell activation; and binds to SHN3 to activate the Wnt/SHN3 signaling pathway. Viridicatol inhibits the expression of pro-inflammatory mediators and cytokines, and promotes osteogenic/chondrogenic differentiation. Viridicatol can be used in studies related to fibrosarcoma, allergy, bacterial infection, fungal infection and osteoporosis .
|
-
-
- HY-N9326
-
-
-
- HY-N1789
-
-
-
- HY-N4185
-
-
-
- HY-N6651
-
-
-
- HY-N6650
-
-
-
- HY-N10002
-
-
-
- HY-N4143
-
-
-
- HY-N1230
-
-
-
- HY-N12177
-
-
-
- HY-N3734
-
|
|
Terpenoids
Labiatae
Samanea saman (Jacq.) Merr.
Diterpenoids
Plants
|
Beta-secretase
Phosphatase
|
|
Deoxyneocryptotanshinone, a natural tanshinone, is a high affinity BACE1 (Beta-secretase) inhibitor with an IC50 value of 11.53 μM. Deoxyneocryptotanshinone shows a promising dose-dependent inhibition of protein tyrosine phosphatase 1B (PTP1B) with an IC50 value of 133.5 μM. Deoxyneocryptotanshinone can be used for Alzheimer's disease research .
|
-
-
- HY-N16588
-
-
-
- HY-N8200
-
-
-
- HY-N7165
-
-
-
- HY-124896
-
|
6-Geranylnaringenin; Mimulone
|
Paulownia tomentosa (Thunb.) Steud.
Scrophulariaceae
Plants
|
Phosphatase
Apoptosis
Autophagy
|
|
Bonannione A (6-Geranylnaringenin; Mimulone), a prenylflavonoid, is an orally active and potent protein tyrosine phosphatase 1B (PTP1B) inhibitor with an IC50 of 14 µM. Bonannione A triggers caspase-dependent apoptosis. Bonannione A induces autophagy through p53-mediated AMPK/mTOR pathway. Bonannione A shows anti-inflammatory, antiradical and anti-cancer activity .
|
-
-
- HY-N3267
-
-
-
- HY-N13199
-
-
-
- HY-N10378
-
-
-
- HY-N10648
-
-
-
- HY-N1783
-
|
|
Microorganisms
Ketones, Aldehydes, Acids
Source Classification
|
Phosphatase
|
|
(24E)-3,4-Secocucurbita-4,24-diene-3,26,29-trioic acid is a potent PTP1B inhibitor, with an IC50 of 0.4 μM. (24E)-3,4-Secocucurbita-4,24-diene-3,26,29-trioic acid exhibits potent PTP1B inhibitory activity without cytotoxicity .
|
-
-
- HY-N12736
-
-
-
- HY-N16415
-
-
-
- HY-N15308
-
-
-
- HY-N12354
-
-
-
- HY-N16508
-
-
-
- HY-N12621
-
-
-
- HY-N7599
-
-
-
- HY-N12915
-
-
-
- HY-163899
-
-
-
- HY-N12761
-
-
-
- HY-N1117
-
-
-
- HY-N2217R
-
-
-
- HY-N0646R
-
-
-
- HY-116474R
-
|
|
Alkaloids
Structural Classification
Monophenols
Microorganisms
Phenols
Quinoline Alkaloids
Source Classification
|
Reference Standards
JNK
β-catenin
NO Synthase
PGE synthase
Fungal
STAT
ERK
MMP
p38 MAPK
Bacterial
NF-κB
Wnt
|
|
Viridicatol (Standard) is the analytical standard of Viridicatol (HY-116474). This product is intended for research and analytical applications. Viridicatol is a quinolone alkaloid with anti-inflammatory, antibacterial, antifungal, osteogenic and chondrogenic activities. Viridicatol reduces the phosphorylation levels of ERK, JNK, p38 and STAT6; inhibits MMP-2, MMP-9, NF-κB signaling pathway and PTP1B; downregulates genes related to mast cell activation; and binds to SHN3 to activate the Wnt/SHN3 signaling pathway. Viridicatol inhibits the expression of pro-inflammatory mediators and cytokines, and promotes osteogenic/chondrogenic differentiation. Viridicatol can be used in studies related to fibrosarcoma, allergy, bacterial infection, fungal infection and osteoporosis .
|
-
-
- HY-N17424
-
-
-
- HY-N14540
-
-
-
- HY-N17455
-
-
-
- HY-N17326
-
-
-
- HY-N17642
-
-
-
- HY-N16588A
-
-
-
- HY-N18297
-
-
-
- HY-N17601
-
-
-
- HY-N13813
-
-
- HY-N19818
-
-
| Cat. No. |
Product Name |
|
Classification |
-
- HY-159694
-
|
ISIS 404173
|
|
Antisense Oligonucleotides
|
|
IONIS PTP1BRx (ISIS 404173) is an antisense inhibitor of protein tyrosine phosphatase 1B (PTP-1B). IONIS PTP1BRx shows antidiabetic activity, and can be used for the study of insulin resistance and type 2 diabetes mellitus associated with obesity .
|
-
- HY-159694A
-
|
ISIS 404173 sodium
|
|
Antisense Oligonucleotides
|
|
IONIS PTP1BRx (ISIS 404173) sodium is an antisense inhibitor of protein tyrosine phosphatase 1B (PTP-1B). IONIS PTP1BRx sodium shows antidiabetic activity, and can be used for the study of insulin resistance and type 2 diabetes mellitus associated with obesity .
|
Your information is safe with us. * Required Fields.
Inquiry Information
- Product Name:
- Cat. No.:
- Quantity:
- MCE Japan Authorized Agent:
